GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Gritstone bio Inc.
Galera is a biotech company whose stock plummeted after the failure of a key clinical trial. Its price chart is a dramatic story of the hopes surrounding its drug and the subsequent crisis, a prime example of binary risk in biotech.
Share prices of companies in the market segment - Oncology immuno-therapy
Gritstone Bio is a biopharmaceutical company developing personalized immunotherapeutic vaccines for the treatment of cancer and infectious diseases. We've classified it in the "Immuno-Oncology" segment. The chart below shows how the market views this cutting-edge and complex biotech sector.
Broad Market Index - GURU.Markets
Gritstone Bio is an oncology company developing personalized T-cell therapy vaccines for cancer treatment. As an innovator in this field, it is included in our GURU.Markets index. The chart below shows the overall market trend. See how Gritstone shares compare to sentiment in the biotech sector.
Change in the price of a company, segment, and market as a whole per day
GRTS - Daily change in the company's share price Gritstone bio Inc.
For Gritstone Bio, Inc., an immuno-oncology company, daily price change is a measure of extreme volatility. It reflects the market's reaction to clinical trial data and is a critical parameter in risk assessment formulas.
Daily change in the price of a set of shares in a market segment - Oncology immuno-therapy
Gritstone Bio develops personalized immunotherapeutics and vaccines for the treatment of cancer and infectious diseases. This is a cutting-edge sector of biotechnology. The chart below illustrates the high volatility typical of this industry, where news can dramatically change a company's valuation.
Daily change in the price of a broad market stock, index - GURU.Markets
Gritstone Bio is a biotech company developing personalized cancer vaccines. Its shares are a bet on a scientific revolution in medicine. Their high volatility, dependent on research results, is part of the dynamic of the innovation sector.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Gritstone bio Inc.
Gritstone bio, Inc.'s year-to-date performance is a story of its unique vaccine platform. Its 12-month market cap is entirely dependent on clinical trial data. The success of its personalized cancer vaccines and universal COVID-19 vaccine could be a breakthrough in immunology.
Annual dynamics of market capitalization of the market segment - Oncology immuno-therapy
Gritstone, as an early-stage biotech company, is a high-risk bet on science. Its performance is completely disconnected from the sector and depends on news about its platform for creating personalized cancer vaccines. Its stock price will reflect the speculative faith of investors.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Gritstone Bio, developing personalized cancer vaccines, is one of the most ambitious stories in biotech. Its performance relative to the market is a clear bet on breakthrough technology. Investors are buying not profits, but the hope of a revolution in oncology, which creates a highly volatile price.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Gritstone bio Inc.
Gritstone is an immuno-oncology company developing personalized vaccines. Its monthly performance is entirely dependent on the results of its clinical trials. Data from its innovative programs is a key event, generating strong investor reaction.
Monthly dynamics of market capitalization of the market segment - Oncology immuno-therapy
Gritstone Bio is a biotech company developing personalized cancer vaccines and treatments for infectious diseases. It's at the cutting edge of immunology. The biotech sector's dynamics reflect the hopes for breakthroughs in this field. Gritstone's story is a risky bet that its platform can "teach" the immune system to attack specific targets.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Gritstone Bio, Inc. is a clinical-stage biopharmaceutical company developing next-generation vaccines for the treatment and prevention of cancer and infectious diseases. The company's future depends on the success of its clinical trials. The broader market chart serves as a backdrop to understand how its cutting-edge scientific platform has impacted its stock price.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Gritstone bio Inc.
Gritstone Bio is a biotech company developing personalized vaccines against cancer and infectious diseases. Its weekly stock price is highly volatile and depends on news about clinical trials of its innovative platform.
Weekly dynamics of market capitalization of the market segment - Oncology immuno-therapy
Gritstone Bio develops personalized immunotherapy drugs for cancer treatment. This is one of the most advanced approaches in oncology. The chart will show whether Gritstone's share price fluctuations are driven by its unique scientific data or reflect the overall hopes and risks associated with the entire field of oncoimmunology.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Gritstone is a biotech company whose stock moves on news about clinical trials. This chart clearly demonstrates how much its performance is driven by scientific news rather than general market trends.
Market capitalization of the company, segment and market as a whole
GRTS - Market capitalization of the company Gritstone bio Inc.
Gritstone bio's market capitalization reflects investor faith in its cutting-edge platform for creating personalized cancer vaccines. Its volatile price is driven by news of clinical trials. This is a high-risk bet that its personalized approach to immunotherapy will prove successful.
GRTS - Share of the company's market capitalization Gritstone bio Inc. within the market segment - Oncology immuno-therapy
Gritstone Bio is a biotech company developing personalized cancer vaccines. Its market share in the pharmaceutical sector is extremely small. Its market cap reflects investors' bet on its cutting-edge scientific platform and potential breakthrough in immunotherapy, which carries a significant risk of clinical failure.
Market capitalization of the market segment - Oncology immuno-therapy
The chart below shows the overall value of the biotech sector. Gritstone bio is a company at the forefront of immuno-oncology, developing personalized cancer vaccines based on T-cell antigens. The potential of this market is enormous, and Gritstone is a bold bet that its unique approach will become a reality.
Market capitalization of all companies included in a broad market index - GURU.Markets
Gritstone is a biotech company developing personalized cancer vaccines based on T-cell therapy. Its market cap is a bet on breakthroughs in immuno-oncology. The chart below shows the economic weight of the advanced cell therapy sector.
Book value capitalization of the company, segment and market as a whole
GRTS - Book value capitalization of the company Gritstone bio Inc.
Gritstone's book value is derived from its scientific platform for developing personalized vaccines against cancer and infectious diseases. The chart tells the story of a biotech company investing in a complex and capital-intensive approach to immunotherapy, building its own unique, yet unproven, intangible asset.
GRTS - Share of the company's book capitalization Gritstone bio Inc. within the market segment - Oncology immuno-therapy
Gritstone Bio develops personalized cancer vaccines. The chart shows its share of actual R&D and manufacturing assets. These are its unique production facilities where a personalized drug is created for each patient.
Market segment balance sheet capitalization - Oncology immuno-therapy
Gritstone Bio is a biotech company developing personalized cancer vaccines. Their value lies in their unique platform and data. The book value chart shows the value of their R&D centers and manufacturing facilities, which are merely the tools for implementing their scientific idea.
Book value of all companies included in the broad market index - GURU.Markets
Gritstone Bio's core assets are its own manufacturing facilities for creating personalized cancer vaccines. The chart below shows how the company built this complex and unique manufacturing base for its innovative platform.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Gritstone bio Inc.
Gritstone Bio develops personalized cancer vaccines. Its assets are a unique technology platform and research data. The chart below visualizes its belief in a revolution in oncology. The market capitalization is a bet on the success of its breakthrough approach and is not tied to tangible assets.
Market to book capitalization ratio in a market segment - Oncology immuno-therapy
Gritstone Bio is a biotech company developing personalized cancer vaccines based on artificial intelligence. Its valuation is based on its advanced and sophisticated scientific platform. The chart shows a high premium to stocks, reflecting investor hopes that its approach will be a breakthrough in cancer treatment.
Market to book capitalization ratio for the market as a whole
Gritstone Bio develops personalized cancer vaccines. This is at the forefront of biotechnology, and the company's value lies in its scientific platform. This chart demonstrates the vast gap between its market valuation, based on hopes for a revolutionary treatment, and its modest tangible assets.
Debts of the company, segment and market as a whole
GRTS - Company debts Gritstone bio Inc.
Gritstone Bio is a biotech company developing personalized vaccines against cancer and infectious diseases. This chart shows how it funds its cutting-edge, yet very expensive, research. The company raises capital from investors and through partnerships to conduct complex clinical trials.
Market segment debts - Oncology immuno-therapy
Gritstone Bio is a biotech company developing personalized vaccines against cancer and infectious diseases. This is one of the most advanced and complex approaches in immunotherapy. This chart illustrates the enormous financial requirements required to advance such breakthrough, yet risky, technologies.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Gritstone bio Inc.
Gritstone Bio is a biotech company developing personalized cancer vaccines. This chart shows its financial structure. For a company working on cutting-edge but highly complex technology, debt is a huge risk. Equity financing is essential.
Market segment debt to market segment book capitalization - Oncology immuno-therapy
Gritstone Bio is a biopharmaceutical company developing personalized cancer vaccines. This chart shows the debt load in the biotech sector. It is an indicator of the company's ability to fund its cutting-edge, yet extremely expensive, research and clinical trials.
Debt to book value of all companies in the market
Gritstone Bio is a biotech company developing personalized cancer vaccines. This is one of the most advanced and complex areas of medicine. This chart of total market debt serves as an indicator of the financial system's willingness to finance such long-term, capital-intensive, and high-risk scientific projects.
P/E of the company, segment and market as a whole
P/E - Gritstone bio Inc.
Gritstone Bio is a biotech company developing next-generation personalized immunotherapeutics for the treatment of cancer and infectious diseases, including COVID-19. This chart reflects investor confidence in its unique platform. The price action is speculative and dependent on clinical trial results.
P/E of the market segment - Oncology immuno-therapy
Gritstone Bio is a biotech company developing next-generation cancer immunotherapies and vaccines against infectious diseases. Their approach is based on stimulating a powerful T-cell response. This chart shows the average valuation for the immuno-oncology sector, reflecting investor hopes for a breakthrough in the development of personalized cancer vaccines.
P/E of the market as a whole
Gritstone Bio is a biotech company developing personalized cancer vaccines. Its valuation is a pure bet on the success of its innovative technology. It is not tied to the general economic cycles illustrated by this chart. Its fate is decided in the clinics and depends on whether its approach can effectively combat tumors.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Gritstone bio Inc.
Gritstone Bio is a biotech company developing personalized immunotherapeutic vaccines against cancer and infectious diseases. This chart reflects investors' confidence in its innovative platform. Future profits depend on the success of clinical trials and the commercialization of this complex approach.
%20P%2FE%20Gritstone%20bio%20Inc.&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Gritstone-bio-Inc.&v=1772513730765 "Chart of the company's future (projected) P/E Gritstone bio Inc.")
Future (projected) P/E of the market segment - Oncology immuno-therapy
Gritstone Bio is a biopharmaceutical company developing personalized immunotherapies for cancer and infectious diseases based on its EDGE platform. The chart reflects average expectations for the oncology segment. GRTS's position relative to this benchmark reflects investors' bet on their cutting-edge approach to creating vaccines targeting individual tumor antigens.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Oncology%20immuno-therapy&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Oncology-immuno-therapy&v=1772513730768 "Future (projected) P/E graph of the market segment - Oncology immuno-therapy")
Future (projected) P/E of the market as a whole
Gritstone Bio is a clinical-stage biopharmaceutical company developing personalized immunotherapies for cancer treatment and vaccines against infectious diseases using its unique platform. This chart of overall market expectations demonstrates investor appetite for funding cutting-edge, yet high-risk, scientific approaches in medicine and vaccinology.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772513730770 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Gritstone bio Inc.
Gritstone Bio is a biotechnology company developing personalized vaccines against cancer and infectious diseases based on mRNA and viral vectors. Its financial outlook is characterized by significant R&D expenditures. Potential profitability depends on the success of its cutting-edge vaccine technologies.
Profit of companies in the market segment - Oncology immuno-therapy
Gritstone Bio is a biopharmaceutical company developing personalized immunotherapeutic drugs for the treatment of cancer and infectious diseases, including next-generation vaccines. This chart shows the overall profitability of the immuno-oncology sector. It reflects the willingness of investors to fund cutting-edge, yet complex, scientific approaches to fighting disease.
Overall market profit
Gritstone Bio is a biotech company developing personalized vaccines against cancer and infectious diseases. This is at the forefront of immunotherapy. The company's success depends on the results of clinical trials. The positive economic backdrop, visible in this chart, is critical to attracting the massive investment required for such complex developments.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Gritstone bio Inc.
Gritstone Bio is a biotech company developing personalized immunotherapeutics for the treatment of cancer and infectious diseases, including COVID-19. This chart reflects analysts' speculative expectations regarding the potential of its complex technology platform.
%20profit%20of%20the%20company%20Gritstone%20bio%20Inc.&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Gritstone-bio-Inc.&v=1772513730785 "Graph of future (projected) profit of the company Gritstone bio Inc.")
Future (predicted) profit of companies in the market segment - Oncology immuno-therapy
Gritstone Bio develops personalized cancer vaccines and infectious disease treatments based on its unique platform. The company's future depends on the success of its clinical programs. This chart reflects forecasts for the entire biotech sector, providing context for assessing the potential and risks of Gritstone's cutting-edge immunotherapy approach.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Oncology%20immuno-therapy&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Oncology-immuno-therapy&v=1772513730785 "Graph of future (predicted) profits of companies in a market segment - Oncology immuno-therapy")
Future (predicted) profit of the market as a whole
Gritstone Bio is a biotechnology company developing personalized cancer vaccines. Its prospects depend entirely on success in clinical development. The overall economic indicators presented in this chart are not directly related to its current operating performance.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772513730789 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Gritstone bio Inc.
Gritstone Bio is a biotech company developing personalized cancer vaccines. Its valuation, shown in this chart, is based not on revenue but on the potential of its cutting-edge scientific platform. The metric's dynamics are a direct market reaction to news of clinical trials of its innovative immunotherapeutic approaches.
P/S market segment - Oncology immuno-therapy
Gritstone Bio is a biotechnology company developing personalized vaccines against cancer and infectious diseases. Future revenue depends on the success of its innovative platform. This oncology chart reflects investor expectations for Gritstone's potential to create a breakthrough in immunotherapy through a personalized approach.
P/S of the market as a whole
Gritstone Bio is a biotech company developing personalized cancer vaccines and treatments for viral diseases. Its approach is based on the use of artificial intelligence to identify unique tumor antigens. This market revenue valuation chart helps understand how highly investors value this cutting-edge and sophisticated scientific approach.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Gritstone bio Inc.
Gritstone Bio is a biotech company developing next-generation personalized immunotherapeutics for the treatment of cancer and infectious diseases, including COVID-19. This chart shows how the market perceives the future commercial potential of its innovative platform. It reflects confidence in its scientific approach and the success of its clinical trials.
%20P%2FS%20Gritstone%20bio%20Inc.&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Gritstone-bio-Inc.&v=1772513730808 "The graph of the company's future (projected) P/S Gritstone bio Inc.")
Future (projected) P/S of the market segment - Oncology immuno-therapy
Gritstone Bio is a biotech company developing personalized immunotherapeutics, including vaccines against cancer and infectious diseases, based on its platform. The company's high valuation reflects investors' confidence in its cutting-edge scientific approach, which could lead to breakthrough treatments.
%20P%2FS%20market%20segment%20graph%20-%20Oncology%20immuno-therapy&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Oncology-immuno-therapy&v=1772513730811 "Future (projected) P/S market segment graph - Oncology immuno-therapy")
Future (projected) P/S of the market as a whole
Gritstone Bio is a biotechnology company developing personalized cancer vaccines. This is one of the most advanced approaches in immuno-oncology. Revenue growth projections presented here do not take into account the potential of such revolutionary treatments.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772513730813 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Gritstone bio Inc.
Gritstone Bio is a biotech company developing personalized immunotherapies for the treatment of cancer and infectious diseases. Being in the clinical stage, it has no commercial revenue. The revenue reflected in the chart likely comes from grants and payments from partners.
Sales of companies in the market segment - Oncology immuno-therapy
Gritstone Bio (GRTS) is a biotechnology company developing personalized immunotherapeutics for cancer treatment and vaccines against infectious diseases. This chart shows revenue in the immuno-oncology sector. Gritstone's platform enables the creation of vaccines that target each patient's unique tumor mutations, opening new horizons in treatment.
Overall market sales
Gritstone Bio is a biotech company developing personalized vaccines against cancer and infectious diseases. Its future depends on the success of its innovative platform. This pattern of overall economic activity affects the availability of capital for the biotech sector. During periods of growth, investors are more willing to fund breakthrough but high-risk scientific projects.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Gritstone bio Inc.
Gritstone Bio is a biotechnology company developing personalized immunotherapies for cancer treatment and vaccines against infectious diseases. Its future revenue depends on the success of clinical trials of its innovative platforms. This chart reflects analyst forecasts, which are essentially an estimate of the commercial potential of its cutting-edge scientific approaches.
%20sales%20of%20the%20company%20Gritstone%20bio%20Inc.&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Gritstone-bio-Inc.&v=1772513730822 "Schedule of future (projected) sales of the company Gritstone bio Inc.")
Future (projected) sales of companies in the market segment - Oncology immuno-therapy
Gritstone Bio is a biopharmaceutical company developing personalized immunotherapies for the treatment of cancer and infectious diseases. This forecast chart reflects potential future revenue from their vaccine platforms. This is an analyst's perspective on the commercial prospects of this cutting-edge approach to medicine.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Oncology%20immuno-therapy&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Oncology-immuno-therapy&v=1772513730827 "Schedule of future (projected) sales of companies in the market segment - Oncology immuno-therapy")
Future (projected) sales of the market as a whole
Gritstone Bio is a biotechnology company developing personalized cancer vaccines and therapeutics for infectious diseases. Its approach is based on the analysis of tumor antigens. This graph reflects the overall investment climate, and Gritstone's research progress is a bet on the future of immunotherapy, which will become truly personalized.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772513730830 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Gritstone bio Inc.
Gritstone Bio is a biotechnology company developing a new generation of vaccines against cancer and infectious diseases using self-amplifying mRNA technology. Its financial performance reflects significant investment in this cutting-edge science. The chart shows current profitability as an investment in the creation of potentially revolutionary vaccines.
Market segment marginality - Oncology immuno-therapy
Gritstone Bio is a clinical-stage biopharmaceutical company developing personalized immunotherapies for cancer and infectious diseases based on its unique platform. This chart reflects its operating expenses. Future profitability depends on the success of its complex but potentially breakthrough scientific approach.
Market marginality as a whole
Gritstone Bio is a biotech company developing personalized cancer vaccines. This is cutting-edge science, requiring massive investment. This total return chart reflects the market's willingness to fund such breakthrough, yet highly risky, projects. Economic growth and investor optimism are key to Gritstone's success.
Employees in the company, segment and market as a whole
Number of employees in the company Gritstone bio Inc.
Gritstone Bio is a biotechnology company developing a new generation of vaccines against cancer and infectious diseases. Its approach is based on the use of artificial intelligence to create personalized immunotherapies. This chart shows the growing team of scientists working at the forefront of oncology.
Share of the company's employees Gritstone bio Inc. within the market segment - Oncology immuno-therapy
Gritstone Bio is developing next-generation personalized immunotherapies for cancer treatment. Creating customized vaccines is an extremely complex scientific and manufacturing process. This chart reflects the company's significant investment in human capital, showing the team of leading scientists and specialists it has assembled to implement this cutting-edge approach in oncology.
Number of employees in the market segment - Oncology immuno-therapy
Gritstone Bio develops personalized immunotherapeutics for cancer treatment. This chart, showing employment in immuno-oncology, illustrates the shift toward personalized medicine. For Gritstone, with its sophisticated technology, the growing number of specialists in this field demonstrates the recognition of the potential of cancer vaccines.
Number of employees in the market as a whole
Gritstone Bio develops personalized immunotherapeutic drugs for cancer treatment. This is one of the most advanced areas in medicine. Funding such complex and long-term R&D projects is possible in a strong economy. The growth in overall employment shown in this chart indicates an environment in which investors are willing to take risks on potentially revolutionary technologies.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Gritstone bio Inc. (GRTS)
Gritstone Bio (GRTS) is a biotech company developing personalized immunotherapeutics (including vaccines) for cancer. This chart shows the valuation of their unique R&D platform. Market capitalization is not tied to the company's state but rather represents the success of their sophisticated technology. This represents pure intellectual capital.
%20of%20the%20company%20Gritstone%20bio%20Inc.%20(GRTS)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Gritstone-bio-Inc.-GRTS&v=1772513730864 "Chart of market capitalization per employee (in thousands of dollars) of the company Gritstone bio Inc. (GRTS)")
Market capitalization per employee (in thousands of dollars) in the market segment - Oncology immuno-therapy
Gritstone Bio develops personalized cancer vaccines, one of the most advanced areas of biotechnology. Its extremely high market capitalization reflects the market's enormous expectations for its ability to create revolutionary treatments tailored to the individual characteristics of a patient's tumor.
%20by%20market%20segment%20-%20Oncology%20immuno-therapy&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Oncology-immuno-therapy&v=1772513730869 "Market capitalization per employee (in thousands of dollars) by market segment - Oncology immuno-therapy")
Market capitalization per employee (in thousands of dollars) for the overall market
Gritstone Bio is a biotech company developing personalized cancer vaccines and therapeutics for infectious diseases. This is cutting-edge science. This chart for Gritstone illustrates how the cost per employee in the immuno-oncology field can be astronomical, reflecting the complexity and potential of their technology platform.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772513730883 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Gritstone bio Inc. (GRTS)
Gritstone Bio is a biotech R&D company working on personalized cancer vaccines. It is not profitable. This chart shows a negative value—the loss (investment) per scientist. This reflects the high cost of cutting-edge immuno-oncology research.
%20Chart%20Gritstone%20bio%20Inc.%20(GRTS)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Gritstone-bio-Inc.-GRTS&v=1772513730885 "Company Profit Per Employee (in thousands of dollars) Chart Gritstone bio Inc. (GRTS)")
Profit per employee (in thousands of dollars) in the market segment - Oncology immuno-therapy
Gritstone Bio develops personalized immunotherapeutic vaccines against cancer. In the cutting-edge field of oncology, the productivity of every scientist and data scientist is paramount. This chart shows the potential value each employee creates, which is an indicator of the company's investment in its unique scientific platform.
%20in%20the%20market%20segment%20-%20Oncology%20immuno-therapy&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Oncology-immuno-therapy&v=1772513730887 "Chart of profit per employee (in thousands of dollars) in the market segment - Oncology immuno-therapy")
Profit per employee (in thousands of dollars) for the market as a whole
Gritstone Bio is a biotech company developing personalized cancer vaccines and mRNA-based therapies for infectious diseases (including COVID-19). This chart shows the average profitability of one employee in the economy. It provides investors with context: the biotech sector operates in an all-or-nothing paradigm, where the return on personnel (scientists) can be enormous if successful.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772513730889 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Gritstone bio Inc. (GRTS)
Gritstone Bio is a biotech company developing personalized mRNA-based vaccines against cancer and infectious diseases. Being in clinical trials, it has no commercial revenue. The chart will show zero, emphasizing that its value lies in the potential of its innovative technology platform.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Gritstone-bio-Inc.-GRTS&v=1772513730891 "Sales chart per company employee Gritstone bio Inc. (GRTS)")
Sales per employee in the market segment - Oncology immuno-therapy
Gritstone Bio (GRTS) is a biotech company developing personalized mRNA-based vaccines for the treatment of cancer and infectious diseases. This chart shows the average revenue per employee in the sector. It is important for assessing R&D efficiency and capital utilization compared to other companies in the immunotherapy field.
Sales per employee for the market as a whole
Gritstone bio (GRTS) is a clinical-stage biotechnology company developing personalized cancer vaccines and vaccines against infectious diseases (including COVID-19) using its self-amplifying mRNA platform. The company has no commercial revenue. This near-zero figure reflects investment in the team of scientists working on this cutting-edge technology.
Short shares by company, segment and market as a whole
Shares shorted by company Gritstone bio Inc. (GRTS)
Gritstone Bio (GRTS) is a biotech company developing personalized cancer vaccines using self-amplifying mRNA (sa-mRNA) technology. This is at the cutting edge of science. This chart shows short interest. The high bearish bets reflect the enormous risks: investors are betting that this highly complex technology will fail in clinical trials. (349)
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Gritstone-bio-Inc.-GRTS&v=1772513730900 "Short Shares Chart for the Company Gritstone bio Inc. (GRTS)")
Shares shorted by market segment - Oncology immuno-therapy
Gritstone Bio (GRTS) is a biotech company developing personalized immunotherapeutic vaccines against cancer and infectious diseases. The chart below represents a general short position in the biotech sector. It demonstrates investor skepticism regarding the success of complex and expensive clinical trials.
Shares shorted by the overall market
Gritstone Bio is developing cutting-edge mRNA cancer vaccines. This is extremely complex and expensive science. This chart illustrates the general fear. When investors are pessimistic, they are unwilling to fund R&D that could take 10 years. They see GRTS as a money-burner and a binary risk (failure/success), preferring to sell the stock and avoid risk.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Gritstone bio Inc. (GRTS)
Gritstone Bio is a biotech company developing personalized mRNA-based vaccines against cancer and infectious diseases. This is R&D at the cutting edge of science. This graph is a "cardiogram" of hope. It "overheats" to the extreme with positive trial data and "cools" when there are delays.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Gritstone-bio-Inc.-GRTS&v=1772513730941 "RSI 14 indicator chart for the company's stock Gritstone bio Inc. (GRTS)")
RSI 14 Market Segment - Oncology immuno-therapy
Gritstone Bio is a biopharmaceutical company developing a new generation of immunotherapies. Its platform uses AI to create personalized vaccines against cancer and infectious diseases. This chart shows the overall "temperature" in the volatile immuno-oncology sector. It helps separate the dynamics of GRTS from the general "hype" or disillusionment in this field.
RSI 14 for the overall market
Gritstone Bio (GRTS) is a biotech company. Like everything in its sector, it's critically dependent on this chart. Market euphoria is an opportunity to easily raise hundreds of millions of dollars for research. Market panic is the risk of running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast GRTS (Gritstone bio Inc.)
Gritstone Bio is a biotech company developing next-generation immunotherapies, including personalized cancer vaccines (based on mRNA) and vaccines for infectious diseases. This chart shows the speculative average price target from analysts, which is almost entirely dependent on their belief in the success of this R&D platform.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-GRTS-Gritstone-bio-Inc.&v=1772513730963 "A chart showing analyst consensus forecasts for the expected stock price. GRTS (Gritstone bio Inc.)")
The difference between the consensus estimate and the actual stock price GRTS (Gritstone bio Inc.)
Gritstone is "personalized" oncology. The biotech company develops custom vaccines (based on AI and neoantigens) for cancer treatment. This chart illustrates the analyst community's opinion on the company's future. It measures the distance between the stock price and the target, reflecting their faith in this complex yet groundbreaking R&D platform.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-GRTS-Gritstone-bio-Inc.&v=1772513730967 "A chart showing the difference between the consensus forecast and the actual stock price. GRTS (Gritstone bio Inc.)")
Analyst consensus forecast for stock prices by market segment - Oncology immuno-therapy
Gritstone Bio is a biotech company developing self-amplifying mRNA vaccines (samRNA) for the treatment of cancer and infectious diseases. This is the "second generation" of mRNA. This chart reflects analysts' overall expectations for the entire immunotherapy sector. It shows whether experts believe in the success of new R&D platforms.
Analysts' consensus forecast for the overall market share price
Gritstone Bio is a biotech company developing personalized "neoantigen" vaccines (based on AI) for cancer treatment. This chart reflects the overall market "risk appetite." For Gritstone, a clinical-stage company with an innovative platform, overall market optimism (risk appetite) is critical for attracting capital for R&D.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Gritstone bio Inc.
Gritstone Bio is a biotech sniper. Their signature feature is an R&D platform (AI) that scans a patient's tumor and predicts unique neoantigens (targets) to create a personalized vaccine against cancer (and COVID). This chart is a pure indicator of faith in their R&D. It doesn't reflect revenue, but rather a speculative valuation of their (very risky) pipeline.
AKIMA Market Segment Index - Oncology immuno-therapy
Gritstone Bio is a cancer immunotherapy company. Their specialty is developing personalized vaccines (GRANITE), which train the immune system to attack the unique mutations of a patient's tumor. This chart compares their composite index to the sector, showing how their personalized approach outperforms others.
The AKIM Index for the overall market
Gritstone Bio is a biotech company developing personalized vaccines for cancer and infectious diseases (GRANITE). This chart, which reflects the market average, is an indicator of risk appetite. It shows the macro backdrop critical for funding this innovative immunotherapy platform.
